Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. AMRN
stocks logo

AMRN

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q4
FY2026Q1
50.62M
-18.76%
-0.430
-64.18%
42.76M
+1.78%
-0.010
-99.58%
40.99M
-43.66%
0.000
-100%
Estimates Revision
The market is revising Upward the revenue expectations for Amarin Corporation plc (AMRN) for FY2025, with the revenue forecasts being adjusted by 11.49% over the past three months. During the same period, the stock price has changed by 7.37%.
Revenue Estimates for FY2025
Revise Upward
up Image
+11.49%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-94.24%
In Past 3 Month
Stock Price
Go Up
up Image
+7.37%
In Past 3 Month
Wall Street analysts forecast AMRN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for AMRN is 10.00 USD with a low forecast of 10.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast AMRN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for AMRN is 10.00 USD with a low forecast of 10.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
1 Hold
0 Sell
Hold
Current: 16.460
sliders
Low
10.00
Averages
10.00
High
10.00
Current: 16.460
sliders
Low
10.00
Averages
10.00
High
10.00
Goldman Sachs
Paul Choi
Strong Sell
Maintains
$20 → $7
2025-04-17
Reason
Goldman Sachs
Paul Choi
Price Target
$20 → $7
2025-04-17
Maintains
Strong Sell
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Amarin Corporation PLC (AMRN.O) is -823.00, compared to its 5-year average forward P/E of -56.27. For a more detailed relative valuation and DCF analysis to assess Amarin Corporation PLC 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-56.27
Current PE
-823.00
Overvalued PE
110.76
Undervalued PE
-223.30

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-115.57
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
225.15
Undervalued EV/EBITDA
-456.28

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
2.18
Current PS
0.00
Overvalued PS
3.08
Undervalued PS
1.29
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

AMRN News & Events

Events Timeline

(ET)
2025-11-09
19:08:52
Amarin reveals new post hoc analysis regarding aspirin usage in REDUCE-IT study
select
2025-10-29 (ET)
2025-10-29
07:08:15
Amarin announces Q3 earnings per share of 2 cents compared to a loss of 6 cents in the same period last year.
select
2025-10-27 (ET)
2025-10-27
08:03:58
Amarin Releases Statement Regarding Recent FDA Action on Fenofibrate Medications
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
11-10Yahoo Finance
New Analysis from REDUCE-IT® on Aspirin Unveiled at AHA Scientific Sessions 2025 Confirms VASCEPA®/VAZKEPA® (Icosapent Ethyl) Lowers Cardiovascular Events in High-Risk Individuals

  • New Analysis on Icosapent Ethyl: A post hoc analysis from the REDUCE-IT study shows that icosapent ethyl significantly reduces cardiovascular events in high-risk patients, regardless of aspirin use, reinforcing its role in comprehensive cardiovascular risk management.

  • FDA Update on Fibrates: The FDA has updated labeling for fibrates, indicating they do not provide cardiovascular benefits when used with statins, highlighting the need for more effective therapies to address residual cardiovascular risk.

  • Commitment to Cardiovascular Care: Amarin Corporation emphasizes its dedication to advancing cardiovascular care and raising awareness about the importance of FDA-approved therapies like VASCEPA (icosapent ethyl) for patients with elevated triglycerides.

  • Efficacy and Safety Profile: The analysis indicates that icosapent ethyl offers cardiovascular protection beyond standard therapies without additional safety concerns, addressing a critical evidence gap in cardiovascular treatment.

[object Object]
Preview
8.5
10-29NASDAQ.COM
GNTA, BBIO, AMRN Surge in After-Hours Trading: Major Biotech Factors Fueling Stock Increases

  • Genenta Science S.p.A. Update: After a significant drop in regular trading due to a $15 million capital raise announcement, Genenta's shares saw a modest recovery in after-hours trading, indicating potential stabilization as investors assess the long-term impact of the company's strategic collaborations.

  • EDAP TMS S.A. Recovery: Despite a sharp decline during the day, EDAP's stock rebounded in after-hours trading, reflecting renewed speculative interest, particularly ahead of upcoming investor meetings at the UBS Global Healthcare Conference.

  • BridgeBio Pharma Inc. Anticipation: BridgeBio's shares rose significantly after hours, driven by investor optimism regarding the upcoming Phase 3 trial results for ADH1, with topline data expected to be released soon.

  • OrthoPediatrics Corp. Financial Performance: Following the release of its Q3 financial results, OrthoPediatrics experienced a surge in after-hours trading, buoyed by revenue growth and FDA approvals, leading to an optimistic revision of its full-year revenue guidance.

[object Object]
Preview
4.0
09-04NASDAQ.COM
Daily Upgrade Report for Validea Kenneth Fisher Strategy - September 4, 2025

  • Validea's Upgrades: Today's upgrades for Validea's Price/Sales Investor model highlight Amarin Corporation PLC (AMRN) and Ebara Corp (ADR) (EBCOY), with AMRN's rating increasing from 40% to 60% and EBCOY's from 68% to 90% based on their fundamentals and valuations.

  • Company Profiles: Amarin focuses on cardiovascular therapeutics, particularly its product Vascepa for reducing triglyceride levels, while Ebara Corp operates in various sectors including energy and environmental services, providing a range of industrial products and solutions.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Amarin Corporation PLC (AMRN) stock price today?

The current price of AMRN is 16.46 USD — it has increased 1.04 % in the last trading day.

arrow icon

What is Amarin Corporation PLC (AMRN)'s business?

Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.

arrow icon

What is the price predicton of AMRN Stock?

Wall Street analysts forecast AMRN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for AMRN is 10.00 USD with a low forecast of 10.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Amarin Corporation PLC (AMRN)'s revenue for the last quarter?

Amarin Corporation PLC revenue for the last quarter amounts to 49.67M USD, increased 17.43 % YoY.

arrow icon

What is Amarin Corporation PLC (AMRN)'s earnings per share (EPS) for the last quarter?

Amarin Corporation PLC. EPS for the last quarter amounts to -0.37 USD, decreased -69.67 % YoY.

arrow icon

What changes have occurred in the market's expectations for Amarin Corporation PLC (AMRN)'s fundamentals?

The market is revising Upward the revenue expectations for Amarin Corporation plc (AMRN) for FY2025, with the revenue forecasts being adjusted by 11.49% over the past three months. During the same period, the stock price has changed by 7.37%.
arrow icon

How many employees does Amarin Corporation PLC (AMRN). have?

Amarin Corporation PLC (AMRN) has 275 emplpoyees as of December 05 2025.

arrow icon

What is Amarin Corporation PLC (AMRN) market cap?

Today AMRN has the market capitalization of 343.62M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free